Quick Navigation
📊 Overview & Key Findings
- The effect size gap is massive: Psilocybin (d=2.0) is 7x more effective than SSRIs (d=0.3)
- Sauna (d=1.7) beats most pharmaceuticals — a single session can produce lasting effects
- Ashwagandha (d=1.3) rivals prescription anxiolytics — available over the counter
- Hardware + Software together produces better outcomes than either alone
- CBT's "gold standard" status is based on volume of research, not effect size
This guide synthesizes research across supplements, peptides, psychedelics, lifestyle interventions, and psychological therapies. Effect sizes (Cohen's d) are used throughout for comparison — a d of 0.2 is small, 0.5 is medium, 0.8 is large, and anything above 1.0 is very large.
🏆 Master Ranking by Effect Size
All interventions ranked by Cohen's d effect size, combining magnitude of effect with quality of evidence.
| Rank | Intervention | Category | Effect Size (d) | Evidence | Best For | Access |
|---|---|---|---|---|---|---|
| 1 | Psilocybin therapy | Psychedelic | 1.5–2.4 | Moderate (8 RCTs) | Depression, treatment-resistant | OR/CO legal, trials |
| 2 | Sauna / Hyperthermia | Lifestyle | 1.66–2.23 | Moderate | Depression | Sauna access |
| 3 | Ashwagandha | Supplement | 1.13–1.62 | High (12 RCTs) | Anxiety | OTC |
| 4 | IV Ketamine | Pharmacological | 1.44–1.52 | High (many RCTs) | Treatment-resistant depression | Clinics ($400-800) |
| 5 | Saffron | Supplement | 0.89–1.62 | High (23 RCTs) | Depression | OTC |
| 6 | Psychodynamic (long-term) | Therapy | 0.98–1.51 | Moderate | Both (grows over time) | Therapist |
| 7 | MDMA-assisted therapy | Psychedelic | 0.7–1.1 | Moderate (Phase 3) | PTSD/trauma | Trials only |
| 8 | ACT | Therapy | 0.47–1.05 | High | Both | Therapist |
| 9 | Curcumin | Supplement | 0.65–2.62 | Moderate (10 RCTs) | Both | OTC |
| 10 | Exercise | Lifestyle | 0.62–0.97 | Very High (200+ RCTs) | Both | Free |
| 11 | Magnesium | Supplement | 0.92 | Moderate (7 RCTs) | Both | OTC |
| 12 | Silexan (Lavender) | Supplement | 0.87 | High | Anxiety | OTC |
| 13 | MBCT | Meditation | 0.79–0.85 | High | Depression | Programs/Apps |
| 14 | CBT | Therapy | 0.53–0.79 | Very High (409 trials) | Both | Therapist |
| 15 | Light Therapy | Lifestyle | 0.48–0.84 | High (11 RCTs) | Depression, SAD | Light box ($30-100) |
| 16 | Kava | Supplement | 0.62–0.82 | Moderate (Cochrane) | Acute anxiety | OTC |
| 17 | Sleep Optimization | Lifestyle | 0.51–0.81 | Very High (65 RCTs) | Both | Free (CBT-I) |
| 18 | MBSR | Meditation | 0.49–0.55 | High | Anxiety, stress | Programs/Apps |
| 19 | EPA Omega-3 | Supplement | 0.43–1.03 | High (36 RCTs) | Depression | OTC |
| 20 | Growth Mindset SSI | Mindset | 0.28–0.60 | Moderate | Adolescents | Free (30-min) |
| 21 | SSRIs | Pharmacological | 0.30 | Very High | Severe depression | Rx |
💊 MDMA Research
Current FDA Status (December 2024)
The FDA rejected Lykos Therapeutics' New Drug Application for MDMA-assisted therapy in August 2024, requiring an additional Phase 3 trial. Despite showing 67-71% remission rates in trials, concerns about blinding, missing safety data, and therapist misconduct allegations led to the rejection.
| Milestone | Outcome |
|---|---|
| Breakthrough Therapy Designation | ✅ Granted 2017 |
| Phase 3 Trial 1 (2021) | 67% remission vs 32% placebo |
| Phase 3 Trial 2 (2023) | 71% remission vs 48% placebo |
| FDA Advisory Committee (June 2024) | ❌ Voted 2-9 against efficacy |
| FDA Decision (August 2024) | ❌ Rejected, requires new Phase 3 |
Mechanism of Action
MDMA creates a unique neurochemical state ideal for therapeutic processing:
MDMA for Shame & Guilt
- Oxytocin surge → self-compassion becomes accessible (shame's antidote)
- Reduced amygdala activity → can look at painful memories without overwhelming self-attack
- Increased MPFC activity → enhanced ability to reframe narratives about self
- Creates "optimal arousal zone" — enough activation to access material, not so much that defenses slam shut
Safety Profile
| Risk Factor | At Therapeutic Doses | Notes |
|---|---|---|
| Neurotoxicity | Low at 1-1.5 mg/kg | Trial doses don't cause lasting damage |
| Acute side effects | Common but transient | Elevated HR, jaw clenching, nausea |
| "Comedown" | 2-4 days | Mood dip as serotonin replenishes |
| Addiction potential | Low | Not a "want to repeat" experience for most |
- Heat + dehydration dramatically enhances neurotoxicity
- Street ecstasy ≠ pure MDMA — ~50% contains adulterants (fentanyl, meth)
- SSRI interaction — blocks effects AND can cause serotonin syndrome
- Heart conditions — significant cardiovascular stress
Current Access Pathways
| Route | Details | Status |
|---|---|---|
| Clinical Trials | ClinicalTrials.gov, MAPS.org | Active enrollment |
| Expanded Access | ~2,000 individuals treated | Limited availability |
| Australia | Legal for prescription since 2023 | Strict regulations |
| Canada | Compassionate access programs | Case-by-case |
🌿 Supplements
Ranked by effect size × evidence quality. Many supplements outperform pharmaceuticals.
Tier 1 Large Effect + Strong Evidence
▼Ashwagandha (Withania somnifera)
Evidence: 12 RCTs, 1002 participants | Best for: Anxiety
Mechanism: Reduces cortisol, enhances GABAergic signaling, adaptogenic
Dose: 300-600mg/day of root extract (KSM-66 or Sensoril)
Synergies: Stacks well with magnesium, L-theanine
Saffron (Crocus sativus)
Evidence: 23 RCTs; comparable to SSRIs | Best for: Depression
Mechanism: Serotonergic modulation, anti-inflammatory
Dose: 30mg/day standardized extract
Safety: Fewer adverse events than SSRIs
Silexan (Lavender Oil)
Evidence: Multiple RCTs; equals lorazepam | Best for: Anxiety
Mechanism: GABA modulation without sedation
Dose: 80-160mg/day (Lavela WS 1265)
Safety: No sedation, no dependence, no withdrawal
Tier 2 Large Effect, Moderate Evidence
▼Curcumin
Effect Size: g = -0.65 to -2.62 (anxiety shows larger effects)
Evidence: 10 RCTs for depression, 5 for anxiety
Mechanism: BDNF upregulation, anti-inflammatory (NF-kB)
Dose: 500-1000mg/day with piperine (increases absorption 2000%)
Magnesium
Effect Size: SMD -0.92
Evidence: 7 RCTs, 325 participants
Mechanism: NMDA receptor modulation, HPA axis regulation
Dose: 200-500mg elemental (glycinate, threonate, or taurate)
Onset: Effects within 2 weeks
Probiotics (Psychobiotics)
Effect Size: SMD -0.96 for depression; best as adjunct (SMD 0.83)
Evidence: 18 RCTs, 1401 patients
Mechanism: Gut-brain axis, inflammation reduction
Key Strains: L. rhamnosus, L. helveticus, B. longum
Tier 3 Moderate Effect, Strong Evidence
▼| Supplement | Effect Size | Evidence | Dose | Best For |
|---|---|---|---|---|
| EPA Omega-3 | SMD -0.43 to -1.03 | 36 RCTs + Mendelian | 1-1.5g/day EPA | Depression |
| Vitamin D | SMD -0.40 to -0.57 | 31 RCTs, 24K pts | 2000-4000 IU/day | Depression (not anxiety) |
| St. John's Wort | = SSRIs | Cochrane review | 300mg TID | Depression (⚠️ drug interactions) |
| SAMe | SMD -0.58 | 23 trials, 2183 pts | 400-1600mg/day | Depression |
| Kava | d = 0.62-0.82 | Cochrane review | 120-240mg kavapyrones | Acute anxiety (limit 8 weeks) |
| Zinc | SMD -0.36 | 5 RCTs | 25-50mg/day + copper | Depression |
| NAC | SMD -0.24 to -0.37 | 12 RCTs | 1000-2750mg/day | Adjunct |
| Creatine | d = 1.13 as SSRI adjunct | 11 RCTs | 5g/day | Women + SSRI |
| L-Theanine | Moderate | 9 RCTs | 200-400mg/day | Acute anxiety |
| Rhodiola | ~1.4x odds improvement | 5 RCTs | 200-600mg/day | Fatigue + mood |
Major CYP3A4 inducer — contraindicated with SSRIs, birth control, and many other medications. Check interactions before use.
🧬 Peptides
Emerging field with varying evidence levels. Most have not undergone rigorous Western clinical trials but show promising mechanisms.
Tier 1 Human Clinical Trials (Russian)
▼Selank
Evidence: Approved in Russia for GAD; multiple human clinical trials
Effect: Comparable to low-dose benzodiazepines without dependence, sedation, or cognitive impairment
Mechanism: Modulates GABA-A receptor, increases BDNF, influences serotonin
Dose: Intranasal 300-600mcg daily; cycle 2 weeks on, 1 week off
Safety: No dependence, withdrawal, or amnesia reported
Best for: Anxiety without benzo downsides
Cerebrolysin
Evidence: Multiple RCTs (CAPTAIN I and II trials); used clinically in Europe/Russia
Effect Size: 61% improvement vs 41% placebo; large effect (0.73) on anxiety
Mechanism: Contains BDNF, CNTF, GDNF, NGF; promotes neuroplasticity
Dose: IM up to 5ml or IV 10-30ml; cycles of 10-20 days
Best for: Depression with cognitive symptoms, TBI
Semax
Evidence: Approved in Russia; human studies for stroke, cognitive impairment
Effect: Significant cognitive improvement; increased plasma BDNF
Mechanism: ACTH analog; increases BDNF and NGF; modulates dopamine/serotonin
Dose: Intranasal 300-600mcg daily; cycle 10-14 days on, 7 off
Caveat: May have anxiogenic component — better for cognition/depression than anxiety
Tier 2 Strong Animal Data, Limited Human
▼BPC-157
Evidence: Extensive animal studies; no published human trials for mood
Animal Effects: Antidepressant effect comparable to standard antidepressants; anxiolytic
Mechanism: Gut-brain axis; modulates dopamine and serotonin systems
Dose: SubQ 250-500mcg daily or oral 500-1000mcg
Caveat: Mixed anecdotal reports — some report anxiety relief, others increased anxiety
Dihexa
Evidence: Preclinical only; no human trials
Effect: 7 orders of magnitude more potent than BDNF in neurotrophic assays
Mechanism: Activates HGF/c-Met pathway; promotes synaptogenesis
Dose: Oral 5-40mg (wide range due to lack of data)
c-Met activation is an oncogenic pathway. No long-term safety studies exist. Highest-risk peptide on this list.
Peptide Stacking
| Combination | Rationale | Cautions |
|---|---|---|
| Selank + Semax | Most popular stack. Semax for cognition/BDNF, Selank for anxiety | Cycle both; may overstimulate |
| BPC-157 + Selank | Gut-brain + anxiolytic | Both affect serotonin; evaluate for MCAS |
🍄 Psychedelics Comparison
Psilocybin and MDMA show the largest effect sizes (d = 1.5-2.4), dwarfing traditional antidepressants (d = 0.3) and even IV ketamine (d = 0.7-1.5). However, access remains the primary barrier.
| Intervention | Effect Size | Response Rate | Duration of Effect | Best For | Access |
|---|---|---|---|---|---|
| Psilocybin | d = 1.38–2.4 | 70-75% | 6-12+ months | Depression, treatment-resistant | OR/CO legal, trials |
| MDMA-AT | d = 0.7–1.1 | 67-71% | 12+ months | PTSD, trauma | Trials only |
| IV Ketamine | g = 1.44–1.52 | 45% | 1-2 weeks | Treatment-resistant, suicidality | Clinics ($400-800) |
| Ayahuasca | d = ~1.0–1.5 | 80%+ | Weeks to months | Treatment-resistant depression | Retreats, religious |
| Esketamine (Spravato) | d = 0.15–0.31 | ~50% | Days (needs maintenance) | Treatment-resistant depression | FDA approved |
| Nitrous Oxide | d = ~0.5–0.7 | Unknown | 24 hours (single) | Treatment-resistant (experimental) | Experimental |
| LSD Microdosing | d = ~0.3–0.5 | Unclear | Unclear | Possibly placebo effect | Illegal |
The Duration Question
This is crucial: Psilocybin's effects persist 6-12+ months after 1-2 doses. Ketamine requires ongoing maintenance every 2-6 weeks. This fundamentally changes the value proposition.
Psilocybin (and other classical psychedelics) appear to produce lasting changes in brain connectivity and neuroplasticity that persist beyond the drug's presence. Ketamine's effects are more transient.
Head-to-Head: Psilocybin vs Escitalopram (SSRI)
🏃 Lifestyle Interventions
If you could only do 3 lifestyle interventions:
- Sauna/Heat Therapy (d = 1.66–2.23) — largest effect, single session can work
- Exercise (d = 0.62–0.97) — best-established evidence
- Sleep Optimization (d = 0.51–0.81) — affects everything else
| Intervention | Effect Size | Evidence | Optimal Protocol | Time to Benefits |
|---|---|---|---|---|
| Sauna/Hyperthermia | d = 1.66–2.23 | Moderate | 20 min at 80°C+, 2-3x/week | 1 week |
| Exercise (walking/jogging) | d = 0.62–0.97 | Very High (200+ RCTs) | 30-45 min moderate, 3-4x/week | Immediate boost; 6-8 weeks full |
| Light Therapy | d = 0.48–0.84 | High (11 RCTs) | 10,000 lux, 30 min morning | 1-2 weeks |
| Sleep Optimization | d = 0.51–0.81 | Very High (65 RCTs) | CBT-I; consistent wake time; 7-9 hrs | 2-4 weeks |
| Cold Exposure | SMD = 0.57–1.00 | Low | 11-15°C, 30 sec–3 min | Immediate (stress); depression unclear |
| Yoga | d = 0.55–0.69 | High | 60 min, 3x/week | 8 weeks |
| Breathwork | g = 0.32–0.40 | Moderate | 15-20 min daily; slow breathing | Immediate; 4+ weeks sustained |
| Intermittent Fasting | SMD = 0.41 | Low (14 studies) | 16:8 or 18:6 | Weeks to months |
Why Sauna Works So Well
A single whole-body hyperthermia session raising core temp to 38.6°C showed effect sizes of d = 2.23 at week 1 and d = 1.66 sustained at week 6. Mechanism: endorphin release, cortisol reduction, prolonged body temperature lowering.
🧠 Therapy Modalities
CBT is the "gold standard" because it has 409 trials (most researched), not because it has the largest effects. When you control for study quality and use real placebos, CBT drops to d = 0.24. Meanwhile, ashwagandha (d = 1.3) and sauna (d = 1.7) show dramatically larger effects.
| Therapy | Effect Size | Evidence Quality | Duration | Best For |
|---|---|---|---|---|
| Psychodynamic (long-term) | d = 0.98–1.51 | Moderate | Grows over time | Both (effects increase at follow-up) |
| ACT | SMD = 0.47–1.05 | High | 8-12 weeks | Psychological flexibility |
| DBT | d = 0.62–1.37 | Moderate | 6-12 months | Emotional dysregulation, BPD |
| CBT | g = 0.53–0.79 | Very High (409 trials) | 8-16 weeks | Both (gold standard) |
| IFS (Internal Family Systems) | Emerging evidence | Low (growing) | Varies | Shame, parts work, trauma |
| Growth Mindset SSI | d = 0.28–0.60 | Moderate | 30 minutes (!) | Adolescents |
CBT in Placebo-Controlled Trials
Recent meta-analysis (2022) of placebo-controlled studies since 2017 found CBT effect size of only Hedges' g = 0.24 for target symptoms. At 6-month follow-up, effects were very small and not significant (g = 0.09). The large effect sizes (d = 0.7-0.8) often cited are vs. waitlist controls, which inflates effects.
🧘 Meditation Deep Dive
Meditation is a hybrid — it's a practice (software) that creates biological changes (hardware). 8 weeks of meditation changes brain structure.
| Type | Effect Size | Evidence | Best For | Duration |
|---|---|---|---|---|
| MBCT (Mindfulness-Based CBT) | g = 0.79–0.85 | High | Depression, relapse prevention | 8-week program |
| MBT for Anxiety Disorders | g = 0.97 | High | Diagnosed anxiety | 8-week program |
| MBSR (Mindfulness-Based Stress Reduction) | g = 0.49–0.55 | High (29 studies) | Stress, general wellbeing | 8-week program |
| General Meditation | d = 0.30–0.63 | High (200+ studies) | Both | Varies |
Why Meditation is "Hybrid"
🧠 Software Effects
- Interrupts rumination cycles
- Develops metacognitive awareness
- Reframes relationship to thoughts
- Builds distress tolerance
⚙️ Hardware Effects
- Amygdala gray matter decreases
- Prefrontal cortex thickens
- Immediate parasympathetic activation
- Lasting changes in stress reactivity
Recommendations
- Depression: MBCT (specifically designed for depression relapse prevention)
- Anxiety: MBSR or app-based (Headspace, Ten Percent Happier)
- Easiest to start: Focused attention meditation (breath focus)
⚙️ Hardware vs Software Analysis
Hardware interventions generally show larger effect sizes than software interventions, but the best outcomes combine both. Pure "software" approaches struggle when the nervous system is dysregulated — you can't "think your way out" of a cortisol-flooded brain.
⚙️ Hardware (Biological)
Average d = 0.8–1.5
- Larger effect sizes overall
- Faster onset (days-weeks)
- Works even when motivation is low
- Creates conditions for healing
- May mask rather than resolve root issues
- Can be expensive or require access
🧠 Software (Psychological)
Average d = 0.5–0.8
- Addresses root causes
- Skills transfer to other life areas
- No physical side effects
- Effects often grow over time
- Requires consistent effort
- Doesn't work when biology is "hijacked"
Signs of a Hardware Problem
(Biology is dysregulated — fix the substrate first)
- Can't motivate to do therapy homework
- Physical symptoms dominate (fatigue, tension, sleep)
- Rumination feels automatic/unstoppable
- Tried therapy but "can't access" emotions
- Symptoms started after physical event
- Strong family history of mood disorders
Start with: Supplements, exercise, sauna, sleep optimization, potentially ketamine
Signs of a Software Problem
(Thought patterns and beliefs are the core issue)
- Can identify specific triggering thoughts/beliefs
- Symptoms tied to specific situations/relationships
- Negative self-talk is prominent and identifiable
- Avoidance behaviors are primary coping
- History of adverse childhood experiences
- Perfectionism, people-pleasing patterns
Start with: CBT, ACT, IFS, psychodynamic therapy
Visual Comparison
EFFECT SIZE (Cohen's d) 0.0 0.5 1.0 1.5 2.0 2.5 | | | | | | |███████████████████████████████| Psilocybin (2.0-2.4) |██████████████████████████████ | Sauna (1.7-2.2) |█████████████████████████ | Ashwagandha (1.1-1.6) |█████████████████████████ | IV Ketamine (1.4-1.5) |███████████████████████ | Psychodynamic LT (1.0-1.5) |████████████████████ | Saffron (0.9-1.6) |████████████████████ | MDMA-AT (0.7-1.1) |███████████████████ | Exercise (0.6-1.0) |███████████████████ | ACT (0.5-1.0) |██████████████████ | MBCT (0.8-0.9) |█████████████████ | DBT (0.6-1.4) |████████████████ | CBT (0.5-0.8) |███████████████ | Meditation (0.5-0.8) |██████████████ | Magnesium (0.9) |█████████████ | Light therapy (0.5-0.8) |████████████ | EPA Omega-3 (0.4-1.0) |███████████ | Growth mindset (0.3-0.6) |█████ | SSRIs (0.3)
💪 Synergistic Stacks
Morning
- Light therapy 30 min
- Ashwagandha 300mg
- EPA Omega-3 1g
- Vitamin D 4000 IU
Midday
- Exercise 30-45 min
Evening
- Magnesium 400mg
- Ashwagandha 300mg
Why it works: Light → circadian reset; Ashwagandha → cortisol down; Exercise → BDNF up; Magnesium → sleep quality
Expected effect: d ≈ 0.8–1.2 combined
Daily Base
- Ashwagandha 600mg
- Magnesium 400mg
- Silexan 160mg
- Probiotic (L. rhamnosus)
As-Needed
- L-theanine 200-400mg
- Kava 120mg (short-term)
Weekly
- Sauna 20 min 2-3x
Add if accessible: Selank 300-600mcg intranasal (strongest anxiolytic without benzo downsides)
Expected effect: d ≈ 1.2–1.5 combined
Daily Base
- Saffron 30mg
- Creatine 5g
- EPA 1.5g
- Curcumin 500mg + piperine
- Morning light 30 min
Weekly
- Sauna 20 min 3x
Monthly (if accessible)
- Ketamine infusion
Why it works: Saffron = SSRI-equivalent; Creatine = brain energy (d=1.13 as SSRI adjunct in women); EPA = proven causal link; Sauna = largest lifestyle effect
Expected effect: d ≈ 1.3–1.8 combined
Immediate
- IV Ketamine series (6 infusions)
4-Week Foundation
- All of Stack 3
- Sauna 3x/week
- Sleep optimization (CBT-I)
When Ready
- Psilocybin therapy (OR/CO)
Rationale: Ketamine provides rapid relief while building foundation. Foundation prevents relapse between sessions. Psilocybin for lasting transformation once stable.
💔 Shame/Guilt-Specific Protocol
Shame triggers physiological shutdown (dorsal vagal response). The body literally can't access self-compassion because the nervous system is in survival mode. Pure "software" approaches struggle — you need to regulate the hardware first.
Create biological safety so emotions become accessible.
- Ashwagandha 600mg/day (lowers cortisol)
- Magnesium 400mg/day (calms nervous system)
- Exercise 30 min 4x/week (BDNF, regulation)
- Sauna 2-3x/week (resets stress response)
Begin processing work once system is regulated.
- IFS therapy weekly — specifically designed for shame/parts work
- MBSR or meditation app daily 15-20 min
- Self-compassion practices (Kristin Neff's work)
For lasting change in self-perception.
Option A: Ketamine-Assisted IFS
- Creates neuroplastic state + therapy
- Dissolves rigid self-narratives
- Available at specialized clinics
Option B: Psilocybin Therapy
- 57-71% remission rates
- Lasting changes in self-perception
- Legal in Oregon/Colorado
Why This Works for Shame
| Component | Effect on Shame |
|---|---|
| Ashwagandha | Lowers cortisol → reduces defensive shutdown |
| Sauna | Endorphins + parasympathetic activation → safety |
| IFS Therapy | Framework for approaching shame without overwhelm |
| Ketamine | Dissolves rigid "I am bad" narratives |
| Psilocybin | Enables seeing self from outside perspective |
Quick wins they'll notice first:
- Ashwagandha → anxiety reduction in 2-4 weeks
- Magnesium → better sleep in 1-2 weeks
- Exercise → immediate mood boost, sustained at 6-8 weeks
- Sauna → mood lift within days
📋 Practical Implementation
Week-by-Week Starter Protocol
Weeks 1-2: Foundation Only
Morning:
- 10,000 lux light box, 30 min with breakfast
- Ashwagandha 300mg (KSM-66)
- EPA Omega-3 1g
- Vitamin D 4000 IU
Evening:
- Magnesium glycinate 400mg
- Ashwagandha 300mg
Cost: ~$40-60/month for supplements
Weeks 3-4: Add Exercise + Heat
- Exercise 30-45 min, 4x/week (walking/jogging fine)
- Sauna 15-20 min, 2-3x/week (or hot bath if no sauna)
Week 5+: Add Condition-Specific
- If anxiety dominant: Add Silexan 160mg
- If depression dominant: Add Saffron 30mg + Creatine 5g
- If trauma/shame: Start IFS therapy
Month 2+: Consider Escalation
If insufficient response:
- Ketamine clinic evaluation
- Psilocybin therapy (if in OR/CO or can travel)
- Clinical trial enrollment
Access Pathways
| Intervention | How to Access | Cost |
|---|---|---|
| Supplements | Amazon, iHerb, health stores | $40-100/mo |
| Sauna | Gym, spa, home unit | $0-100/mo |
| Light therapy | Amazon light box | $30-100 one-time |
| Ketamine | Ketamine clinics nationwide | $400-800/infusion |
| Psilocybin | Oregon/Colorado legal, clinical trials | $1,500-3,500/session |
| MDMA | Clinical trials (ClinicalTrials.gov) | Free in trials |
| IFS therapy | Psychology Today finder | $150-250/session |
| Selank | Research peptide suppliers | $50-100/month |
📚 Sources & References
Meta-Analyses & Systematic Reviews
- CBT 409-Trial Meta-Analysis (2023) — World Psychiatry
- BMJ Exercise Meta-Analysis (2024)
- Psilocybin 12-Month Follow-up
- Ashwagandha BJPsych Meta-Analysis
- Saffron 23-RCT Review
- Ketamine Lancet Meta-Analysis
- MBCT/MBSR Meta-Analysis
- ACT Overview of Reviews
Key Clinical Trials
- MDMA MAPP1 Phase 3 Study
- MDMA MAPP2 Phase 3 Study
- Psilocybin vs Escitalopram (NEJM)
- UCSF Heat Therapy Research
- Growth Mindset 9-Month Outcomes
Additional Resources
- MAPS MDMA Research
- ClinicalTrials.gov — Find active trials
- Psychology Today — Find IFS therapists